Johnson & Johnson

JNJ: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
%%>LOCK|W#$LOCK|Yb%$F$<

Johnson & Johnson: Intra-Cellular Boosts Growth in Neuroscience and Fits With Industry Trend

On Jan.13, Johnson & Johnson announced that it plans to acquire Intra-Cellular and its schizophrenia and depression drug Caplyta for $14.6 billion.

Sponsor Center